We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-1.57%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$6.49B
AUM Growth
-$396M
Cap. Flow
-$220M
Cap. Flow %
-3.39%
Top 10 Hldgs %
43.16%
Holding
163
New
23
Increased
16
Reduced
43
Closed
16

Top Buys

Rank Stock Value
1
LIAN
LianBio American Depositary Shares
LIAN
+$643M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$97.4M
3
BLU
BELLUS Health Inc.
BLU
+$50.7M
4
ISO
IsoPlexis Corporation Common Stock
ISO
+$45.4M
5
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$33.3M

Top Sells

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$79.2M
2
NVTA
Invitae Corporation
NVTA
+$50.6M
3
BEAM icon
Beam Therapeutics
BEAM
+$46.8M
4
DBVT
DBV Technologies
DBVT
+$37.7M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$30M

Sector Composition

Rank Sector Weight
1 Healthcare 85.98%
2 Miscellaneous 13.04%
3 Financials 0.8%
4 Industrials 0.09%
5 Consumer Staples 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATXS
101
DELISTED
Astria Therapeutics
ATXS
$6.91M 0.11%
1,281,197
-678,455
-35% -$4.46M
SGHT icon
102
Sight Sciences
SGHT
$447M
$6.85M 0.11%
390,000
– –
CNCE
103
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$6.77M 0.1%
2,150,641
– –
PNT
104
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$6.69M 0.1%
1,193,995
-48,884
-4% -$367K
AORT icon
105
Artivion
AORT
$1.24B
$6.64M 0.1%
+326,318
New +$6.58M
ACCD
106
DELISTED
Accolade Inc
ACCD
$6.03M 0.09%
228,774
-51,000
-18% -$1.67M
ZY
107
DELISTED
Zymergen Inc. Common Stock
ZY
$5.91M 0.09%
883,332
– –
PEAR
108
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
$5.74M 0.09%
+926,232
New +$8.27M
CLOV icon
109
Clover Health Investments
CLOV
$2.48B
$5.58M 0.09%
1,500,000
– –
PRVB
110
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$5.33M 0.08%
948,481
– –
ONCR
111
DELISTED
Oncorus, Inc.
ONCR
$5.27M 0.08%
999,812
-99,998
-9% -$774K
FULC icon
112
Fulcrum Therapeutics
FULC
$288M
$5.2M 0.08%
294,118
– –
NVNO
113
enVVeno Medical
NVNO
$6.48M
$5.15M 0.08%
+22,332
New +$6.29M
FUSN
114
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$5.12M 0.08%
1,227,017
-27,590
-2% -$172K
PRTA icon
115
Prothena Corp
PRTA
$428M
$4.94M 0.08%
100,000
– –
DALS
116
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
$4.91M 0.08%
500,000
– –
TBIO
117
DELISTED
Telesis Bio, Inc. Common Stock
TBIO
$4.59M 0.07%
23,611
– –
OBIO icon
118
Orchestra BioMed
OBIO
$363M
$4.54M 0.07%
450,000
– –
DRIO icon
119
DarioHealth
DRIO
$66.1M
$4.25M 0.07%
16,393
– –
NEPT
120
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$4.12M 0.06%
7,183
– –
RPID icon
121
Rapid Micro Biosystems
RPID
$57.7M
$4.1M 0.06%
385,693
+35,693
+10% +$557K
SONX
122
DELISTED
Sonendo, Inc.
SONX
$3.85M 0.06%
+668,505
New +$6.02M
ACHL
123
DELISTED
Achilles Therapeutics
ACHL
$3.78M 0.06%
755,375
– –
AXSM icon
124
Axsome Therapeutics
AXSM
$10.7B
$3.04M 0.05%
80,420
– –
PMVP icon
125
PMV Pharmaceuticals
PMVP
$72.7M
$2.89M 0.04%
125,000
-176,714
-59% -$4.27M
3 4
5
6 7

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q4 2021 Portfolio in Review

As of Q4 2021, Perceptive Advisors held 163 positions worth $6.49B, down 5.7% from $6.88B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Perceptive Advisors withdrew a net $220M in Q4 2021, closing 16 positions and reducing 43 holdings. Its most notable exit was Atea Pharmaceuticals, an estimated $79.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 86% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Perceptive Advisors opened a new position in LianBio American Depositary Shares worth $347M.

  • Perceptive Advisors's largest Q4 2021 buy was LianBio American Depositary Shares: 56,319,960 shares worth $347M.
  • Perceptive Advisors added most to Apellis Pharmaceuticals in Q4 2021, an estimated $32.9M increase.
  • Perceptive Advisors's biggest Q4 2021 reduction was Invitae Corporation, cutting an estimated $50.6M.
  • Perceptive Advisors fully exited Atea Pharmaceuticals in Q4 2021, selling an estimated $79.2M.
  • Perceptive Advisors's ten largest holdings make up 43% of its $6.49B portfolio in Q4 2021.
  • Perceptive Advisors opened 23 new positions and closed 16 in Q4 2021.
  • Perceptive Advisors's portfolio value fell 5.7% quarter-over-quarter to $6.49B.

Based on Perceptive Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.